Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms-Reference-Cited by-同舟云学术

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

Published:2020-11 Issue:4 Volume:1 Page:100093
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Szlosarek Peter W.,Phillips Melissa M.,Pavlyk Iuliia,Steele Jeremy,Shamash Jonathan,Spicer James,Kumar Sanjeev,Pacey Simon,Feng Xiaoxing,Johnston Amanda,Bomalaski John,Moir Graeme,Lau Kelvin,Ellis Stephen,Sheaff Michael

Funder

Higher Education Funding Council for England

Queen Mary University of London

University of London

National Institute for Health Research

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference52 articles.

1. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases;Klebe;Mod Pathol,2010

2. Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma;Vigneswaran;Ann Thorac Surg,2017